Todos os estudos
RecrutamentoFASE3INTERVENCIONISTA

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

This important study is investigating a new medication, inclisiran, for children aged 2 to 11 who have a rare and severe inherited condition called homozygous familial hypercholesterolemia (HoFH). Children with HoFH have very high levels of 'bad' cholesterol (LDL-C) from birth, which can lead to serious health problems. The study aims to find out if inclisiran is a safe and effective way to help lower these high cholesterol levels. It will compare inclisiran against a placebo (a dummy drug) over one year, followed by another year where all participants receive inclisiran. Participants will already be on their usual cholesterol-lowering treatments. The findings could help improve treatments for children with HoFH.

Em resumo

Status
Recrutamento
Fase
FASE3
Patrocinador
Novartis Farmacêutica
Meta de inscrição
9
Iniciar
28 Fev 2025
Conclusão estimada
15 Apr 2029

Sobre o que é este estudo?

This research study is about a condition called homozygous familial hypercholesterolemia, often shortened to HoFH. This is a very rare genetic condition where children are born with extremely high levels of 'bad' cholesterol (LDL-C). This isn't caused by diet or lifestyle, but by faulty genes inherited from both parents. Because their cholesterol is so high from a young age, children with HoFH are at a much higher risk of developing serious heart problems early in life.

The study is looking at a new medicine called inclisiran. It's designed to help the body get rid of more 'bad' cholesterol from the blood. The main purpose of this study is to see if inclisiran is safe for children with HoFH, if their bodies can handle it well, and if it's effective at lowering their high cholesterol levels when added to their existing treatments.

This study is a 'Phase 3' trial, which means it's a key step in checking if new medicines work and are safe before they can be made widely available. The results of this study will help doctors and researchers understand if inclisiran could be a valuable new treatment option for children living with HoFH.

Pontos principais

  • Targets very high cholesterol (HoFH) in children aged 2-11.
  • Compares a new medicine, inclisiran, to a placebo first.
  • Aims to check safety, how well it's tolerated, and effectiveness.
  • Study lasts for two years, with regular clinic visits.
  • A participação é voluntária, e você pode se retirar a qualquer momento.

Quem pode ser elegível?

This study is looking for children aged between 2 and 11 years old. To be considered, children must have a confirmed diagnosis of homozygous familial hypercholesterolemia (HoFH) through genetic testing. They also need to have high levels of 'bad' cholesterol (LDL-C) that are above a certain point, even with their current treatments.

Children currently taking cholesterol-lowering medicines like statins or ezetimibe must have been on a stable dose for at least one month before joining the study, with no plans to change these doses. If a child receives a treatment called LDL-apheresis (a procedure to remove cholesterol from the blood), they must have been doing this regularly for at least three months, and this treatment schedule needs to stay the same during the first part of the study.

Some children would not be able to take part. This includes those with a specific genetic mutation called a 'null mutation' in both their LDLR genes, or if they've recently used or had a poor response to similar cholesterol-lowering medications. Children with other medical problems, like active liver disease or certain serious health conditions, would also be excluded.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Is your child aged between 2 and 11 years old?
  2. Does your child have a confirmed diagnosis of homozygous familial hypercholesterolemia (HoFH)?
  3. Is your child's LDL-C ('bad' cholesterol) still high despite their current treatments?
  4. Has your child been on a stable dose of their current cholesterol medicines for at least one month?
  5. Does your child currently weigh enough for their age group?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If your child takes part in this study, it will last for two years. For the first year, your child would be randomly assigned to receive either the study medicine, inclisiran, or a placebo (a dummy treatment that looks like inclisiran but has no active medicine). Neither you nor the study team will know which treatment your child is receiving during this first year. Both inclisiran and the placebo are given as injections.

After the first year, all children in the study will then receive inclisiran for another year. Throughout the study, your child will continue their usual cholesterol-lowering treatments. There will be regular visits to the clinic, which will involve check-ups, blood tests to monitor cholesterol levels and general health, and assessments to see how your child is feeling and responding to the treatment. The total duration of participation in the study for each child would be two years.

Riscos e benefícios potenciais

Taking part in a clinical trial like this could offer potential benefits, such as access to a new treatment (inclisiran) that might lower your child's cholesterol levels more effectively than current options. While inclisiran has been studied in adults, its safety and effectiveness in children with HoFH are still being evaluated. There could be potential risks, including discomfort from injections, side effects from the medication (which will be carefully monitored), and the possibility that the treatment may not work for every child or your child may receive a placebo first. It's very important to remember that participation is completely voluntary, and you have the right to withdraw your child from the study at any time, for any reason, without it affecting their ongoing medical care.

Localizações (19)

  • UC San Francisco Medical Center
    Código postal verificado
    São Francisco, Estados Unidos· Recrutamento
  • Childrens National Hospital
    Código postal verificado
    Washington D.C., Estados Unidos· Recrutamento
  • Washington Univ School Of Medicine
    Código postal verificado
    St Louis, Estados Unidos· Recrutamento
  • Primary Childrens Medical Center
    Código postal verificado
    Salt Lake City, United States· Recrutamento
  • Site de Investigação da Novartis
    Código postal verificado
    Viena, Áustria· Recrutamento
  • Site de Investigação da Novartis
    Código postal verificado
    Pequim, China· Recrutamento
  • Site de Investigação da Novartis
    Código postal verificado
    Frankfurt am Main, Alemanha· Recrutamento
  • Site de Investigação da Novartis
    Código postal verificado
    Ioannina, Greece· Recrutamento
  • Site de Investigação da Novartis
    Código postal verificado
    Thessaloniki, Greece· Recrutamento
  • Site de Investigação da Novartis
    Código postal verificado
    Kota Bharu, Malaysia· Recrutamento
  • Site de Investigação da Novartis
    Código postal verificado
    Amsterdã, Países Baixos· Recrutamento
  • Site de Investigação da Novartis
    Código postal verificado
    Bloemfontein, South Africa· Recrutamento

Perguntas frequentes

What is homozygous familial hypercholesterolemia (HoFH)?

HoFH is a rare genetic condition where children are born with very high levels of 'bad' cholesterol (LDL-C) due to faulty genes inherited from both parents, leading to an increased risk of heart problems.

What is inclisiran?

Inclisiran is a new investigational medicine designed to help lower 'bad' cholesterol (LDL-C) levels in the blood.

Will my child get the actual medicine?

For the first year, your child will either receive inclisiran or a look-alike placebo. For the second year, all children will receive inclisiran.

How long will the study last for my child?

If your child participates, their involvement in the study will last for two years.

Can we stop participating at any time?

Yes, you are free to withdraw your child from the study at any point, and their regular medical care will not be affected.

Como saber mais

Novartis Farmacêutica

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "Study to Evaluate Safety, Tolerability and Efficacy of Incli…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.